AstraZeneca approached Gilead about potential merger – Bloomberg News
LONDON (Reuters) – Britain’s AstraZeneca Plc (AZN.L) has approached U.S. rival Gilead Sciences Inc (GILD.O) about a possible merger that…
Bristol-Myers wins $752 million in U.S. patent case against Gilead
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage,…
Half of lymphoma patients alive three years after Gilead cell therapy treatment: study
(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after…
FDA panel backs Gilead’s HIV prevention drug Descovy, except in women
(Reuters) – An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc’s combination drug to reduce the…
Gilead invests $5 billion to deepen ties with biotech Galapagos
(Reuters) – U.S. antiviral drugmaker Gilead Sciences (GILD.O) will invest $5.1 billion in a major expansion of its partnership with…
Gilead Sciences snares Roche veteran O’Day as CEO
(Reuters) – Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG’s Daniel O’Day as its new chief executive, tapping…
UK rejects Gilead’s CAR-T cancer cell therapy as too expensive
LONDON (Reuters) – A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify…